Oncology

FDA grants fast review to BMS’ first-line lung cancer combo

https://pharmaphorum.com/news/fda-grants-fast-review-to-bms-first-line-lung-cancer-combo/

Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca

https://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/

UK accounts for 12% of cell and gene therapy trials – report

https://pharmaphorum.com/news/uk-accounts-for-12-of-cell-and-gene-therapy-trials-report/

NICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCC

https://pharmaphorum.com/news/nice-rejects-astellas-xospata/

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

https://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/

Oncology Forecasting Training New Jersey

https://pharmaphorum.com/events/oncology-forecasting-training-new-jersey/

GSK’s CEO Walmsley aiming for six new approvals in 2020

https://pharmaphorum.com/news/gsks-ceo-walmsley-aiming-for-six-new-approvals-in-2020/

Astellas to work with Adaptimmune to develop ‘off the shelf’ T-cell therapies

https://pharmaphorum.com/news/astellas-to-work-with-adaptimmune-to-develop-off-the-shelf-t-cell-therapies/

Blueprint gets first approval as FDA backs stomach cancer drug

https://pharmaphorum.com/news/blueprint-gets-first-approval-as-fda-backs-stomach-cancer-drug/

1 2 3 4 5 >»

Close in 10 seconds

Pharmaphorum.com

Search